28 April 2026
UAE
Testvox FZCO
Fifth Floor 9WC Dubai Airport Freezone
Inside an FDA Premarket Submission: What Medical Device Makers Get Wrong About Cybersecurity
19 June 2026
11:11 MIN Read time 
BY
Divya Prakash
Bringing a connected medical device to market requires navigating a complex regulatory environment. Since the FDA gained explicit statutory authority over device cybersecurity under Section 524B of the FD&C Act, the submission landscape has transformed. Security is no longer an isolated technical hurdle; it is a fundamental element of clinical patient safety.
During rigorous evaluations of connected health technologies, similar to the hands-on reviews executed by Healthcare Delivery (HD) networks and cybersecurity advisory groups—certain structural patterns emerge. Many device makers treat cybersecurity as a final paperwork exercise rather than a core engineering discipline. This disconnect leads directly to significant delays, Refuse to Accept (RTA) actions, and extensive deficiency letters.
To clear the regulatory hurdle smoothly, development teams must shift their mindset. By analyzing real pain points discovered during deep technical audits, manufacturers can better understand what reviewers are actually looking for.
The 5 Most Common Cybersecurity Mistakes in FDA Premarket Submissions
Reviewing a flawed submission often reveals a common theme: a sharp contrast between excellent clinical engineering and weak software security habits. Five specific mistakes consistently trigger regulatory pushback.
1. Treating the Threat Model as a Static Compliance Form
Many engineering teams complete a threat model simply to check a box. They download a standard template, list generic threats like “unauthorized user gains access,” and offer vague mitigations like “password required.”
The FDA expects a dynamic, granular threat model that maps the specific architecture of the device. It must detail every hardware interface, data flow path, and third-party API. If your threat model fails to analyze how a bad actor could exploit a maintenance port or intercept Bluetooth Low Energy data in transit, the reviewer will question the depth of your entire security strategy.
2. Submitting an Uncurated Software Bill of Materials (SBOM)
Making a list of open-source parts without explaining what they do is a big mistake. A good Software Bill of Materials must be something that a machine can read it has to be organized. It has to include all the dependencies.
One thing that people do wrong is they list a library but they do not say what smaller parts it needs to work. If your Software Bill of Materials has parts that are known to be vulnerable and you do not have a plan to fix them the person reviewing it will stop away.
3. Lack of Closed-Loop Traceability
Reviewers expect to see a single, unbroken chain of evidence. Every identified threat must connect to a specific security requirement, which must map to a design feature, and finally link to a clear verification test report.
When a submission scatters threat models, software requirements, and test logs across unrelated documents without a clear traceability matrix, the reviewer cannot verify that the device is actually resilient.
4. Vague or Absent Post-Market Vulnerability Plans
A lot of companies that make medical devices only care about getting the okay from the people in charge. They do not think about what will happen when the device is actually being used. The Food and Drug Administration needs a plan for managing cybersecurity after the device is on the market.
This plan is really important. Many companies do not do a job with this plan. They do not say how they will watch for problems with the device work with others to share information about these problems or send out safe updates to devices that people are already using. The Food and Drug Administration requires a plan, for this. Companies need to have a Post-Market Cybersecurity Management Plan.
5. Overlooking the Impact of Unresolved Anomalies
Every complex software system contains known bugs or anomalies at launch. In medical device submissions, manufacturers often dismiss minor software anomalies as “low risk” without evaluating their security implications. A bug that causes a simple display lag might seem harmless clinically, but if an attacker can exploit that lag to cause a buffer overflow, it becomes a critical security risk.
Real Examples of Submissions Rejected for Cybersecurity Deficiencies
The true impact of these mistakes becomes clear when examining the specific language used in actual FDA deficiency letters. These examples highlight the exact technical issues that cause submissions to stall.
Example A: The Incomplete Penetration Test
A manufacturer submitted a connected patient monitor and included an executive summary stating that automated vulnerability scans showed no critical bugs. The FDA issued a major deficiency letter with the following feedback:
“The submission lacks objective evidence of comprehensive boundary analysis and penetration testing. The provided automated scanning logs do not simulate real-world attack vectors, such as privilege escalation via physical USB interfaces or reverse-engineering of firmware updates. Provide a full penetration testing report executed by an independent entity, including the methodology, exploit attempts, and verification of remediation for all identified vulnerabilities.”
Example B: The Disconnected Risk Matrix
A developer of an AI-driven diagnostic app mapping to a cloud infrastructure failed to link security failures to clinical safety outcomes. The reviewer’s rejection response read:
“The security risk assessment does not bridge the gap to patient safety. The threat model identifies the potential for unauthorized data modification on the cloud server but fails to evaluate how altered diagnostic data could lead to an incorrect clinical decision or delayed treatment. Revise the risk management files to demonstrate that security risks have been evaluated using the same safety criteria applied to hardware and software failures.”
How to Audit Your Submission Before It Reaches the FDA
To avoid catastrophic timeline delays, you must conduct an internal audit that mirrors the FDA’s evaluation process. Do not rely solely on the engineers who wrote the code to verify its security.
First, establish an independent review team to verify your Traceability Matrix. Select an asset, trace it to the threat model, confirm the specific cryptographic mitigation used, and locate the exact page of the test report that proves the control works. If you find a single gap in this chain, fix it before submitting.
Second, audit your SBOM against real-time vulnerability databases. Use automated tools to ensure that no component in your code contains an unmitigated vulnerability. If a library has an active flaw that cannot be patched before submission, you must include a formal technical justification explaining why the flaw cannot be exploited within your device’s unique architecture.
Third, review your End-User Labeling. The FDA wants to ensure that hospital IT staff and clinicians have the information they need to keep the device secure. Check your instructions for use to confirm they clearly explain how to configure network settings, manage user accounts, and recognize a potential security incident.
Fixing Cybersecurity Gaps After an FDA Deficiency Letter
If you receive a deficiency letter or a hold notice, do not panic. The worst thing you can do is submit a rushed, defensive reply that fails to answer the reviewer’s core concerns.
Begin by organizing a multidisciplinary response team that includes regulatory experts, software architects, and cybersecurity specialists. Carefully break down the FDA’s letter line by line. Reviewers often ask for very specific evidence, such as proof of code signature validation or an updated threat model for a specific wireless protocol.
[Deficiency Letter Received]
│
▼
[Line-by-Line Technical Analysis]
│
▼
[Execute Remediation Testing / Update SBOM & Traceability]
│
▼
[Construct Delta Documentation Response Package]
When updating your files, use Delta Documentation. Do not simply drop a revised 400-page document into the file and expect the reviewer to find the changes. Provide a clear summary document that explicitly states what was altered, why it addresses their concern, and exactly where the new verification data lives. If the FDA requests deeper penetration testing, execute the tests completely, document the vulnerabilities discovered, and show exactly how your team patched those gaps.
The Commercial Reality of Secure by Design
Building a device and getting all the right documents takes a lot of time, money and effort.. If you make security a top priority from the start it’s the best way to move forward.
When you design your product to be secure from the beginning you save your company from delays and recalls later on. This way you create a product that hospitals and healthcare organizations can trust. As a result advanced medical technology stays safe, reliable and focused on taking care of patients.
You make sure that your product helps healthcare delivery organizations provide the care possible. A secure product also helps you avoid problems that can hurt your companys reputation.
Making security a part of your design helps you build a strong product. This product can help doctors and nurses do their jobs with confidence. They can focus on patients without worrying about the technology.
You should think about security, from the start to avoid fixes later. This approach helps you create a product that’s both innovative and secure.
28 April 2026
17 June 2026
ABOUT TESTVOX
Testvox is a software testing company help your product reach its full potential. Get full cycle testing for your mobile and web applications while ensuring all quality assurance standards are met... Read More
100+
Applications
Assured
Assured
5 Star Rating
5 Star Rating
“By participating in our release lifecycle, Testvox's standard QA process has helped us to launch quality products faster.”
Rima Hudaifa
Manager | Cadvil
Manager | Cadvil
